Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Nov 14, 2024
Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025
Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M
Read more at globenewswire.com2.5
+0.37 (+17.37%)
Find more stocks in the Stock Screener
SPRO Latest News and Analysis
2 days ago - ChartmillUnusual volume stocks in Friday's sessionLet's explore the current happenings on the US markets on Friday. Below, you'll find the stocks exhibiting unusual volume in today's session.
3 days ago - ChartmillThe trading volume of these stocks is deviating from the norm in today's session.Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session.
3 days ago - ChartmillThese stocks are making the most noise in today's session.Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.
